SIMPLAAFY Clinical Trial
NCT: NCT06521463 · ACTIVE_NOT_RECRUITING
Publicidade
Resumo breve
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
Fonte oficial
Ver no ClinicalTrials.gov →Dados provenientes da API do ClinicalTrials.gov. Para consultar o estado mais recente, veja o registo oficial.